MedTrace Logo

Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome

NCT01359917 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2011-06-13

No results posted yet for this study

Summary

The hypotheses of this study were that:

1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression.
2. Treatment of HIV lipodystrophy using autologous fat transfer, polylactic acid or Bio-alcamid, is associated with an improvement in psychological morbidity and anatomical volume of treated areas.
3. The DI3D system is a valid and reproducible method of recording and measuring facial 3-D volume.

Conditions

  • HIV-Associated Lipodystrophy Syndrome

Sponsors & Collaborators

  • NHS Lothian

    lead OTHER_GOV

Principal Investigators

  • Kenneth J Stewart, FRCSPlast · NHS Lothian

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-07-31
Completion
2009-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01359917 on ClinicalTrials.gov